[The efficacy of the eubiotic bifacide when used in the combined antibacterial therapy of newborn infants with infectious-inflammatory diseases].
The efficacies of bifacid and bifidumbacterin were studied comparatively in the correction of intestinal biocenosis in 60 newborns with infectious inflammatory diseases and intestine disfunction treated with massive doses of antibacterial drugs. The study showed that the use of bifidumbacterin was accompanied by significant disturbances in the biocenosis and by development of the intestinal syndrome. The protective action of the drug was observed after a short-term use only of one antibiotic and when the course of the bifidum therapy was continued after discontinuation of the treatment with antibacterial drugs. The use of bifacid was accompanied by a rapid (by the 2nd or the 5th day fo the treatment) and stable normalization of the stools and a marked improvement of the patient general state. The clinical efficacy of bifacid was much higher than that of bifidumbacterin. At the background of the bifacid therapy there was observed correction of the intestinal microflora composition due to normalization of the count of Bifidobacterium, Lactobacillus and Colibacillus as well as to eradication of opportunistic pathogens.
Kushnareva
M V
MV
Dement'eva
G M
GM
Chernonog
I N
IN
Frolova
M I
MI
Feklisova
L V
LV
Rebrova
T N
TN
D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001644:Bifidobacterium; D001688:Biological Products / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination; D005243:Feces / Q000382:microbiology; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007422:Intestines / Q000382:microbiology; D007779:Lactobacillus acidophilus
D000900:Anti-Bacterial Agents; D001688:Biological Products; C010546:bifidobacterin